1st Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$2,300,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
STEPHANIE A. DYSON —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4385 (117th), H.R. 1319 (117th)

Medicare/Medicaid MMM

H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
STEPHANIE A. DYSON —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5376 (117th), H.R. 2139 (117th), S. 908 (117th), H.R. 2071 (117th)

Trade (domestic/foreign) TRD

International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions

LobbyistCovered position, as disclosed
JOHN DEOUDES —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR)

Bills named: S. 1854 (117th)

Taxation/Internal Revenue Code TAX

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions. H.R.1304- American Innovation and R&D Competitiveness Act of 2021 H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.

LobbyistCovered position, as disclosed
JOHN DEOUDES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5376 (117th), H.R. 1304 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.